BioTelemetry Inc. [NASDAQ: BEAT] gained 4.95% on the last trading session, reaching $45.13 price per share at the time. The company report on July 30, 2020 that BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results.
Posts Strong Results and Ramps Up Business Development Activity.
BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended June 30, 2020.
BioTelemetry Inc. represents 34.29 million in outstanding shares, while the company has a total market value of $1.47 billion with the latest information. BEAT stock price has been found in the range of $42.86 to $45.47.
If compared to the average trading volume of 363.85K shares, BEAT reached a trading volume of 1220523 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioTelemetry Inc. [BEAT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BEAT shares is $54.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BEAT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for BioTelemetry Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 11, 2020. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Neutral. The new note on the price target was released on September 02, 2020, representing the official price target for BioTelemetry Inc. stock. Previously, the target price had yet another raise to $58, while SunTrust analysts kept a Buy rating on BEAT stock.
The Average True Range (ATR) for BioTelemetry Inc. is set at 1.61, with the Price to Sales ratio for BEAT stock in the period of the last 12 months amounting to 3.38. The Price to Book ratio for the last quarter was 4.03, with the Price to Cash per share for the same quarter was set at 2.58. Price to Free Cash Flow for BEAT in the course of the last twelve months was 21.21 with Quick ratio for the last quarter at 2.40.
Trading performance analysis for BEAT stock
BioTelemetry Inc. [BEAT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.22. With this latest performance, BEAT shares gained by 6.16% in over the last four-week period, additionally plugging by 44.42% over the last 6 months – not to mention a rise of 9.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BEAT stock in for the last two-week period is set at 67.35, with the RSI for the last a single of trading hit 76.16, and the three-weeks RSI is set at 60.83 for BioTelemetry Inc. [BEAT]. The present Moving Average for the last 50 days of trading for this stock 41.24, while it was recorded at 42.06 for the last single week of trading, and 44.41 for the last 200 days.
BioTelemetry Inc. [BEAT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BioTelemetry Inc. [BEAT] shares currently have an operating margin of +15.43 and a Gross Margin at +62.46. BioTelemetry Inc.’s Net Margin is presently recorded at +6.80.
Return on Total Capital for BEAT is now 12.41, given the latest momentum, and Return on Invested Capital for the company is 5.55. Return on Equity for this stock inclined to 8.81, with Return on Assets sitting at 4.43. When it comes to the capital structure of this company, BioTelemetry Inc. [BEAT] has a Total Debt to Total Equity ratio set at 58.48. Additionally, BEAT Total Debt to Total Capital is recorded at 36.90, with Total Debt to Total Assets ending up at 29.46. Long-Term Debt to Equity for the company is recorded at 55.91, with the Long-Term Debt to Total Capital now at 35.28.
Reflecting on the efficiency of the workforce at the company, BioTelemetry Inc. [BEAT] managed to generate an average of $17,555 per employee. Receivables Turnover for the company is 6.27 with a Total Asset Turnover recorded at a value of 0.65.BioTelemetry Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.50.
BioTelemetry Inc. [BEAT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BioTelemetry Inc. posted 0.52/share EPS, while the average EPS was predicted by analysts to be reported at 0.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BEAT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioTelemetry Inc. go to 25.00%.
An analysis of insider ownership at BioTelemetry Inc. [BEAT]
There are presently around $1,470 million, or 96.90% of BEAT stock, in the hands of institutional investors. The top three institutional holders of BEAT stocks are: BLACKROCK INC. with ownership of 5,335,588, which is approximately 6.353% of the company’s market cap and around 2.20% of the total institutional ownership; ARROWMARK COLORADO HOLDINGS LLC, holding 4,557,224 shares of the stock with an approximate value of $205.67 million in BEAT stocks shares; and VANGUARD GROUP INC, currently with $173.41 million in BEAT stock with ownership of nearly -0.017% of the company’s market capitalization.
Positions in BioTelemetry Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 111 institutional holders increased their position in BioTelemetry Inc. [NASDAQ:BEAT] by around 1,545,936 shares. Additionally, 107 investors decreased positions by around 2,098,832 shares, while 31 investors held positions by with 28,928,237 shares. The mentioned changes placed institutional holdings at 32,573,005 shares, according to the latest SEC report filing. BEAT stock had 32 new institutional investments in for a total of 413,342 shares, while 24 institutional investors sold positions of 659,428 shares during the same period.